RAPSODI - PRe-clinicAl studies of a PSA-based human vaccine candidate targeting visceral, cutaneOus and mucocutaneous Leishmaniasis and Development of the associated procedures for further clinical trials
Agency: Cordis | Branch: FP7 | Program: CP-SICA | Phase: HEALTH-2007-2.3.4-2 | Award Amount: 4.00M | Year: 2009
The global aim of RAPSODI is : to develop a human vaccine candidate against most or all Leishmania species that cause the most severe leishmaniasis in the world. An unique vaccinal solution will thus be provided to protect against the various clinical phenotypes (namely visceral, cutaneous and mucocutaneaous leishmaniasis, VL, CL and ML respectively). to establish all the associated procedures required for the subsequent clinical trials, such as the selection of the appropriate patients and assessment of vaccine efficiency. For that purpose, an international consortium constituted of countries from endemic areas (India, Peru, Tunisia, Spain and France) and embracing multi-disciplinary approaches has been set-up. Based on successful results on VL dogs, the best VL animal model to date, RAPSODI will propose a second generation human-compatible vaccine candidate and confirm its activity in pre-clinical studies. As the chosen antigen is common to most, if not all, Leishmania species, an ambitious universal immunoprotective response is being sought. RAPSODI will also address the question of population selection in order to ascertain relevant and meaningful clinical trials and vaccination campaigns. Indeed, resistant individuals, when involved in either vaccinated or placebo groups, represent important bias to the analysis of the results. RAPSODI will investigate further the parasitological, immunological and genetic features of such clinical status, and will subsequently apply the generated knowledge to the development of assays and field tests, which represent stand-alone results. The package (vaccine candidate \ diagnostic/prognostic tools) proposed by RAPSODI represents a global solution, and as such is believed to have a real impact on the worldwide leishmaniasis problem.
Agency: Cordis | Branch: FP7 | Program: CP-SICA | Phase: HEALTH-2007-2.3.4-2 | Award Amount: 4.10M | Year: 2009
This project will focus on the preclinical development of a DNA vaccine for human visceral leishmaniasis. The project is based upon the DNA vaccine technology and immunomodulators developed at Mologen AG (Berlin, Germany), which are in clinical development for cancer and 3-5 known antigens that already have demonstrated profiles of protection in animal models of leishmaniasis. Antigens will be selected on the basis of preset criteria to assure protection in high proportion of target populations and against many different species of Leishmania. In vitro and in vivo models will be used to evaluate the prophylactic and therapeutic efficacy of the DNA vehicle with selected antigens alone and in combination with and without immunomodulator. Full toxicology studies will be performed on selected candidate vaccines. Training in preclinical development and clinical trials (ICH-GCP) are an important part of the proposal. Sites will be selected and ready to initiate clinical trials at the end of this project (3 years).
Indian Council Of Medical Research, Post Graduate Institute of Medical Education and Research | Date: 2013-11-19
A vaccine for protection against multiple serotypes of Shigella sp., comprising a putative heat shock protein (EL PGI II), and Hypothetical Protein (EL PGIV) is provided.
Indian Council Of Medical Research | Date: 2014-04-25
This invention relates to a culture medium for cultivation of Leishmania promastigotes, comprising inorganic salts, organic constituents and peptone/hydrolystate and at least one plant extract.
Indian Council Of Medical Research | Date: 2014-01-09
Provided herein is a compound represented by Formula (I) (Transitmycin) effective against bacterial and viral pathogens.
Indian Council Of Medical Research | Date: 2014-05-05
Provided herein is a drug delivery system for curcumin comprising fibrinogen, thrombin and curcumin.
Sree Chitra Tirunal Institute for Medical Science, Technology and Indian Council Of Medical Research | Date: 2014-05-20
This invention relates to an albumin-curcumin conjugate for application in cancer therapy, including albumin and curcumin.
Indian Council Of Medical Research and The King's University | Date: 2014-03-04
Provided herein are primers and probes for the detection of Hepatitis B virus and Hepatitis C virus in a sample, a reaction mixture for multiplex real time PCR for the simultaneous detection and quantitation of Hepatitis B and C and a test kit based on multiplex real time PCR for the simultaneous detection and quantitation of Hepatitis B and C.
Indian Council Of Medical Research | Date: 2014-03-12
Provided herein is a process for the production of Cyclosporin-A (Cyc-A) including the steps of inoculating a nutrient medium with the fungus Tolypocladium sp., strain NRRL No. 18950 followed by cultivation under static conditions to obtain a fermented medium with the fungal biomass, and harvesting the biomass and subjecting the harvested biomass to extraction followed by purification to obtain pure Cyc-A. The nutrient medium includes glucose, glycerol, casein acid hydro lysate, malt extract, peptone, and L-valine.
Indian Council Of Medical Research | Date: 2014-07-02
Provided herein are RNAi agents for inhibition of Chikungunya virus. The present disclosure provides RNAi agents for inhibition of Chikungunya virus, particularly by targeting the E2 gene and nsP1 gene or both of the Chikungunya virus; the RNAi agents comprising of the entire nucleotide sequence set forth is SEQ ID 1 or SEQ ID 5 or combination thereof; or comprising of 15 or more contiguous nucleotides as set forth is SEQ ID 1 or SEQ ID 5 or combination thereof along with the addition nucleotides from the contiguous region of the E2 and nsP1 target gene. The invention further provides a RNAi composition for reducing the E2 protein and nsP1 protein level of Chikungunya virus and inhibition of Chikungunya virus replication. The combination of RNAi agents provides an excellent therapeutic composition for treatment of Chikungunya virus infection.